>>Description of the research protocol "ARTEMIS "

A randomized, double blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in Patients with Immunoglobin A (IgA) nephropathy (ARTEMIS-IGAN)
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Nephrologie clinique
Brugmann identifier : ARTEMIS
EudraCT identifier : 2018-000075-33


Involved department : Nephrology-dialysis
Principal investigator : Pozdzik
Sponsor : Omeros
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.